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ABSTRACT
Hormone-suppression therapies are used for the treat-
ment of breast cancer in the adjuvant and metastatic 
settings alike. However, side effects—including hot 
flashes—are frequently reported by patients as a cause 
of therapy discontinuation. This paper presents an 
overview of hormonal therapies and the evidence-
based management options for hot flashes, summa-
rized in a treatment algorithm.
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1.  INTRODUCTION
In 2008, an estimated 22,400 women in Canada were 
diagnosed with breast cancer, making that disease the 
most common cancer in women. Treatment includes 
any combination of surgery, chemotherapy, and ra-
diation therapy. For women with cancers positive for 
the estrogen or the progesterone receptor (or both), 
hormone suppression is an additional option. Because 
hormone-suppressive treatment can span five or more 
years, care is often shared with or transferred to family 
physicians and community nurse practitioners.
In premenopausal women, the ovaries produce 
about 95% of circulating estrogen; in postmenopausal 
women, conversion or aromatization of androstene-
dione to estrone in peripheral tissues is the major 
source of estrogen. Approximately half of all women 
diagnosed with breast cancer will have a hormone-
sensitive tumour. Blocking uptake of estrogen at the re-
ceptor level or suppressing estrogen and progesterone 
production therefore becomes a goal of treatment.
2.  OVERVIEW OF HORMONE THERAPIES
Tamoxifen, a selective estrogen receptor modulator, 
has both antagonist and agonist properties, blocking 
the effect of estrogen in breast tissue, but showing 
estrogen-like activity in other tissues. The indication 
for the use of tamoxifen has been expanded to include 
adjuvant treatment of both pre- and postmenopausal 
women. Male breast cancers commonly express the 
estrogen and progesterone receptors and can also be 
treated with tamoxifen.
Unlike tamoxifen, fulvestrant is a pure estrogen 
receptor antagonist with no agonist effects. It works 
by both downregulating and degrading the estrogen 
receptor. It is given once monthly as an injection. 
Currently, it is indicated for use only in hormone-
sensitive metastatic breast cancer.
The identification of aromatase as an essential 
enzyme in the peripheral conversion of testosterone 
to estradiol led to the development of further op-
tions for hormone suppression. Aromatase inhibitors 
are used only in postmenopausal women to prevent 
stimulation of ovarian estrogen production through 
negative feedback to the hypothalamus and pituitary 
(analogous to the functional properties of fertility 
drugs). Current agents in this class include anastro-
zole, letrozole, and exemestane.
Hormone suppression is now standard treatment 
for pre- and postmenopausal women with advanced 
and early forms of hormone-sensitive breast cancer. 
Clinical trials such as a t a c  (Anastrozole versus Ta-
moxifen Alone or in Combination), b i g  (Breast Inter-
national Group) 1-98, and i e s (Intergroup Exemestane 
Study) have shown a small but significant additional 
benefit of aromatase inhibitors alone or in sequential 
combination with tamoxifen in improving disease-
free survival 1–3. Other trials are ongoing.
Almost all national and international guidelines 
recommend inclusion of an aromatase inhibitor in 
the treatment plan for hormone-positive tumours in 
postmenopausal women. However, for both pre- and 
postmenopausal women, frequently reported side effects 
include hot flashes, arthralgia, weight gain, hair thin-
ning, dyspareunia, vaginal dryness, and loss of libido. 
In some cases, these side effects may be severe enough 
for patients to stop, independently reduce the dosage 
of, or otherwise alter potentially life-saving treatment 
regimens. Information from clinical trials has revealed 
that approximately 25% of women do not adhere to 
therapy and that this percentage increases to 50% 
for women not in clinical trials 4. Because aromatase 
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inhibition or tamoxifen treatment is intended to last 
for at least 5 years, successful management of these 
side effects becomes paramount in increasing patient 
compliance and optimal outcome. The present review 
focuses on management options for one of these side 
effects: hot flashes.
3.  CLINICAL DESCRIPTION AND 
PATHOPHYSIOLOGY
Hot flashes are commonly defined as recurring 
transient episodes of flushing and sweating, with a 
sensation of heat, often accompanied by palpitations 
or anxiety, and sometimes followed by chills 5. A 
population-based survey comparing women having 
breast cancer with women in the general population 
determined that breast cancer survivors were 5.3 times 
more likely than women in the general population to 
experience menopausal symptoms 6.
Several theories have been posited for the 
pathophysiology of hot flashes. A decline in estrogen 
has been suggested to cause a change in the ther-
moregulatory set point in the anterior portion of the 
hypothalamus 7. The thermoregulatory nucleus initi-
ates perspiration and vasodilatation to keep core body 
temperature within a well-regulated range called the 
thermoregulatory zone 8. Researchers have demon-
strated a narrowing of the zone between sweating and 
shivering in symptomatic women, so that small eleva-
tions within the zone cause a change in hormones or 
neurotransmitters, producing a hot flash 9. Yet correla-
tions of the frequency and severity of hot flashes with 
plasma or serum estrogen levels are poor, suggesting 
that other mechanisms may be involved 7.
Serotonin has repeatedly been proved to be an im-
portant regulator of body temperature, and its action 
appears to be time- and dose-dependent 10. For ex-
ample, drug-induced excess of 5-hydroxytryptamine 
has been noted to induce malignant hyperthermia 11. 
The thermoregulatory set point has been suggested to 
possibly depend on a balance of two or more serotonin 
receptors 12. Changes in the balance, possibly related 
to the direct or indirect action of estrogen, could 
theoretically induce a vasomotor response.
Functional estrogen receptors have been found 
in human vascular smooth muscle, suggesting that 
estrogen may also have a direct and important role in 
vascular function 13. Recent research has also shown 
a correlation between plasma estradiol levels and 
baroreflex sensitivity 14.
The regulation of core body temperature is likely 
to be ultimately found to involve complex interactions 
of norepinephrine, estrogen, testosterone, serotonin, 
and endorphins in neuroendocrine pathways.
Hot flashes emerged as a significant adverse effect 
in all of the aromatase inhibitor trials (Table i). The 
t a r g e t  trial (Trial to Assess Response to Gefitinib in 
EGFR-mutated Tumors) compared anastrozole with 
tamoxifen as first-line treatment in postmenopausal 
women with advanced breast cancer. Hot flashes were 
reported in 19.6% of women receiving anastrozole as 
compared with 18.8% of those receiving tamoxifen 15. 
In the a t a c  adjuvant trial comparing anastrozole with 
tamoxifen, 35.7% of women on anastrozole reported 
hot flashes as compared with 40.9% of women on ta-
moxifen (p < 0.0001) 16. Letrozole and tamoxifen were 
compared in the b i g  1-98 trial, and hot flashes were 
reported in 33.5% of women receiving letrozole and 
in 38% of those receiving tamoxifen (p < 0.001)a. The 
i e s trial compared the steroidal aromatase inhibitor ex-
emestane with tamoxifen. In that trial, hot flashes were 
reported in 42% of patients treated with exemestane and 
in 39.6% of those receiving tamoxifen (p = 0.082) 3.
Little information is available about the duration or 
severity of hot flashes, but the i e s trial did publish qual-
ity-of-life data indicating that this symptom decreased 
over time 17. Some predictors of increased hot flash 
severity or frequency are known. These include previ-
ous history of estrogen replacement therapy, history of 
moderate to severe hot flashes during menopause in 
postmenopausal women, premature treatment-induced 
menopause at a young age, obesity, and smoking (direct 
relationship with number of cigarettes smoked) 18.
4.  REVIEW OF MANAGEMENT OPTIONS
In 2004, a nurse-run hot flash clinic was started at the 
London Regional Cancer Program. The purpose of 
a  Thurlimann B, for the b i g 1-98 Collaborative. Letrozole as adjuvant 
endocrine therapy for postmenopausal women with receptor-pos-
itive breast cancer: first results of i b c s g  18-98/b i g  1-98. Presented 
at the Ninth International Conference on Primary Therapy of Early 
Breast Cancer; January 26, 2005; St. Gallen, Switzerland
t a b l e  i  Incidence of hot flashes in the major trials of aromatase inhibitors
Reference Trial Hot flashes (%) with p Value
short name Anastrozole Tamoxifen Letrozole Exemestane
Bonneterre et al., 2001 1 a t a c 35.7 40.9 0.0001
Bonneterre et al., 2003 15 t a r g e t 19.6 18.8 Not reported
Coombes et al., 2004 3 i e s 39.6 42 0.082
Coates et al., 2007 2 b i g 1-98 38 33.5 0.00183
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the clinic was to evaluate evidence-based treatment 
of hot flashes and to advance symptom management 
research. A stepwise approach based on efficacy data, 
tolerability, and local clinical experience is suggested 
for management (Figure 1, Table ii).
Inclusion of a survey of side effects as part of the 
follow-up assessment of women receiving hormone-
suppressive therapy is imperative. The initial assessment 
of hot flashes should include onset, baseline number 
and severity, effect on measures of quality of life such 
as sleep and work, and any known patterns or triggers. 
Often, patterns emerge and links can be made with trig-
gers such as caffeine, smoking, and alcohol. Reduction 
of these risk factors is recommended. It is sometimes 
helpful to review lifestyle interventions such as dressing 
in layers, use of cotton clothing and bedding, strategic 
placement of electric fans, and the carrying of cold 
drinks. Reusable cooling bandanas containing polymer 
crystals may be helpful. They can be soaked in cold 
water for 10–30 minutes and tied around the neck for a 
long-lasting cooling effect. Results from these changes 
are usually seen within the first 1 to 2 weeks of use.
In small, controlled investigations, progressive 
muscle relaxation and paced respiration techniques 
have been shown to significantly reduce objectively 
measured hot flash occurrence 19,20. In a larger ran-
domized controlled trial of 150 women with primary 
breast cancer who were trained in deep-breathing 
techniques, muscle relaxation, and guided imagery, 
hot flash severity declined significantly over 1 month. 
f i g u r e  1  Treatment algorithm for hot flashes, based on the experience of the London Regional Cancer Program.84
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Distress also significantly declined, but no difference 
in quality of life between the control group and the 
treatment group was observed 25.
Hypnosis may also provide a non-pharmacologic 
option for women who prefer to avoid medications. 
In 2005, a case report of the successful use of hyp-
nosis to treat hot flashes and rheumatic symptoms 
was published 27. In a subsequent randomized trial 
of hypnosis as an intervention for hot flashes, a 68% 
reduction in hot flash scores was demonstrated in 60 
breast cancer survivors as compared with a control 
group. Additional benefit was seen in parameters such 
as sleep, anxiety, and depression 24.
Estrogen replacement, the most effective treat-
ment for menopausal symptoms, is generally not 
recommended after a diagnosis of breast cancer. The 
h a b i t s  (Hormonal Replacement Therapy After Breast 
Cancer Diagnosis—Is It Safe?) trial randomized 434 
women with a previous diagnosis of breast cancer to 
receive either hormone replacement therapy (h r t ) 
or best supportive care without hormones 28,29. The 
endpoint of the trial was any new breast cancer event. 
After 2.1 years, 26 women in the h r t  group (versus 
8 in the no-h r t  group) had experienced a new breast 
cancer event (relative hazard: 3.5; 95% confidence 
interval: 1.5 to 8.1). The trial was terminated Decem-
ber 17, 2003, because of unacceptable risk.
Breast cancer patients suffering hot flashes are of-
ten bombarded with information from well-intentioned 
friends and family members regarding alternative and 
complementary remedies, and those remedies are seen 
by many women with breast cancer as a more attrac-
tive option than traditional medicines. Unfortunately, 
few placebo-controlled trials of non-pharmacologic 
agents have been conducted, and those that have been 
conducted show marginal benefits at best 30. Other 
t a b l e  ii  Review of treatment options for hot flashes in breast cancer patients
Reference
and management option
Effect Reduction (%) in Placebo p Value
Composite  
hot flash score
Severity Frequency
(% response)
Freedman and Woodward, 1992 19
Paced respiration Reduced distress 39 0.02
Freedman et al., 1995 20
Paced respiration Reduced distress 44 0.001
Loprinzi et al., 2000 21
Oral clonidine 0.1 mg once daily Improved quality of life 34.2 21.1 0.001
11.7 8.5 0.18
42.6 24.1 0.002
Stearns et al., 2003 22
Venlafaxine 75 mg daily Improved quality of life and libido 46 19 0.001
61 27 0.001
Pandya et al., 2005 23
Gabapentin 300 mg daily Decreased pain, worse appetite 28 18 0.0002
41 18
33 21 0.0001
Gabapentin 900 mg daily Decreased pain, worse appetite 49 21 0.0001
Elkins et al., 2008 24
Hypnosis Improved mood and sleep,  
decreased interference with daily life
68 Not used 0.001
Fenton et al., 2008 25
Relaxation training Reduced distress 50 22
(clinically
nonsignificant)
Not used 0.0001
Sexton et al., 2007 26
Oxybutynin 2.5 mg twice daily Improved Improved
(retrospective chart review)85
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studies are problematic because of small sample size 
and conflicting results. Most of these remedies are 
phytoestrogens that are structurally similar to estradiol. 
Phytoestrogens can be found in foods such as beans, 
seeds, and grains. They include products such as black 
cohosh, red clover, evening primrose oil, and soy, and 
depending on the dose, they work either to block es-
trogen receptors or to mimic estrogen. Their effect on 
an estrogen-sensitive breast cancer cell is unknown, 
and at the present time there is not enough evidence 
to advise women that these products are safe.
Clinical trials of pharmacologic agents have noted the 
significant placebo effect that any intervention can have 
on hot flashes. It has been reported in numerous clinical 
trials that the placebo effect can decrease hot flashes by 
approximately 50% 8. Data collected from patient diaries 
and outcomes are typically reported in two ways: using 
a composite hot flash score consisting of the frequency, 
duration, and mean severity of each episode; or using sepa-
rate effects, such as change in frequency and severity.
A few pharmacologic agents have shown varying 
degrees of efficacy for treating hot flashes. For some 
of these, side effects limit their usefulness; others 
show statistical benefit, but not clinically significant 
reductions in symptom frequency or intensity. The 
more successful agents include selective serotonin 
reuptake inhibitor (s s r i) antidepressants, megestrol 
acetate, and gabapentin. Antihypertensives such as 
clonidine have shown modest benefit.
Clonidine, a centrally active alpha agonist that re-
duces vascular reactivity and norepinephrine release, is 
used principally for the management of hypertension. 
It is available in pills and transdermal patches. Trans-
dermal clonidine was found to reduce the frequency 
of hot flashes by 20% and the severity by a modest 
10% 31. In another trial, Pandya et al. randomized 
194 postmenopausal women on adjuvant tamoxifen 
therapy to receive either a placebo or oral clonidine 
0.1 mg daily for 8 weeks. Decrease in frequency of hot 
flashes was greater for the clonidine group (38%) than 
for the placebo group (20%), with benefit also noted 
in measures of intensity and duration 32. Other studies 
have shown increasing benefit with higher doses 33.
The s s r i antidepressants have also shown efficacy, 
with the greatest response noted in the breast cancer 
population. Loprinzi et al. conducted a randomized 
placebo-controlled trial of venlafaxine in 191 breast 
cancer survivors complaining of hot flashes 21. Within 
that group, 69% were receiving tamoxifen. The trial 
randomized women to one of four treatment groups: 
three groups received venlafaxine in doses of 37.5 mg, 
75 mg, and 150 mg; the fourth group received placebo. 
After 4 weeks, benefit was seen in the 75 mg dose 
group, with 63% of participants reporting more than 
50% reduction in hot flashes. No additional benefit 
was seen by increasing the dose to 150 mg. A later 
study by Evans et al. confirmed these results in a non–
breast cancer population 34. Other antidepressants in 
this class have also shown efficacy, although concern 
has arisen that some are producing the response by 
blocking the efficacy of an active tamoxifen metabo-
lite, endoxifen, which utilizes the same CYP2D6 path-
way in the liver 22. The data suggest that citalopram 
and venlafaxine are least likely to effect CYP2D6 
activity and that paroxetine and fluoxetine are more 
potent inhibitors and should be avoided 35.
The anticonvulsant gabapentin has been studied for 
hot flash management. A 2005 study by Pandya et al. 
randomized 420 women with breast cancer and experi-
encing at least 2 hot flashes in 24 hours to one of three 
groups: gabapentin 300 mg daily, gabapentin 900 mg 
daily, or placebo 23. After 8 weeks, the 300 mg dose group 
showed a modest 20% reduction in hot flashes, but the 
900 mg dose group showed a reduction of approximately 
46%. Interestingly, three quarters of the patients in the 
900 mg dose group requested and were granted permis-
sion to increase their doses beyond the 900 mg, and they 
achieved a 67% decrease in hot flash severity.
Megestrol is an oral progestogen that has an-
titumour activity in postmenopausal patients after 
failure of other endocrine therapies. A crossover study 
of megestrol versus placebo demonstrated that hot 
flashes were reduced by 85% with megestrol 20 mg 
twice daily 36. However, in vitro studies have shown 
that progestational agents may increase or accelerate 
breast cancer development or progression, making 
megestrol a poor choice for management of hot 
flashes in women. In contrast, it is a very effective 
treatment for men with prostate cancer who are on 
hormone manipulation and suffering hot flashes.
In 2007, a case series using oxybutynin for man-
agement of hot flashes was reported by members of the 
breast disease site team at the London Regional Cancer 
Program. This antimuscarinic agent was observed to 
reduce hot flashes, providing a complete response in ap-
proximately 70% of patients who had been refractory to 
other treatments. The recommended dose is 2.5 mg either 
once or twice daily; side effects typical of anticholinergic 
medications are generally mild and well tolerated 26.
5.  SUMMARY
Hot flashes are a significant problem for quality of life 
in breast cancer patients. They likely contribute to poor 
compliance with hormone-suppressive therapies. Family 
physicians, oncologists, and nurses can play an important 
role both in assessing hot flashes and in reviewing and 
tailoring treatment options to individual patient needs.
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